3/24/2023 0 Comments Rstudio confidence interval![]() Treatment costs for older men with early and late prostate cancer are already high and projected to rise in the following decades. Furthermore, the median age of men who develop the metastatic disease is considerably older, and the median age of those who die due to prostate cancer is eighty years. While the overall mortality rate is predicted to remain steady, the number of men aged 70 and older who die from prostate cancer will nearly double by 2040. Nearly 70% of PC deaths occur in men aged ≥ 75. ![]() However, at the time of diagnosis, 60% of patients are 65 years or older, and by 2040, this percentage will rise to 70%. The average age at which prostate cancer (PC) is diagnosed in western populations is 66 years old. Age-standardized incidence and mortality are 68 and 10 per 100,000, respectively, in more developed regions. Prostate cancer is the fourth most common cancer worldwide. Conclusions: Baseline G8 screening is recommended for mCRPC patients aged ≥70 to optimise ARPIs in vulnerable individuals, including early introduction of palliative care. and setting of treatment (i.e., post-ABI/ENZ) for rPFS only ( p < 0.001 and p = 0.01, respectively) age ≥78 years for OS only ( p = 0.008). At the MVA, independent prognostic factors for both worse rPFS and OS were Geriatric G8 assessment ≤ 14 ( p < 0.001 and p = 0.004) and PSA decline ≥50% ( p < 0.001 for both) time to castration resistance ≥ 31 mo. With a median follow-up of 15.4 months (mo.), the median rPFS was 26.0 mo. Results: Overall, 234 patients were enrolled with a median age of 78 years (73–82) 86 were treated with abiraterone (ABI) and 148 with enzalutamide (ENZ). ![]() Unsupervised median values and literature-based thresholds where available were used as cut-offs for quantitative variables. Cox regression univariable and multivariable analyses for radiographic progression-free (rPFS) and overall survival (OS) were performed. ![]() Methods and Materials: The Meet-URO network ADHERE was a prospective multicentre observational cohort study evaluating and monitoring adherence to ARPIs metastatic castrate-resistant PC (mCRPC) patients aged ≥70. However, prognostic factors relevant to their outcome with ARPIs are still little investigated. Introduction: Androgen receptor pathway inhibitors (ARPIs) have been increasingly offered to older patients with prostate cancer (PC). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |